New Immunotherapy Trials Offer Hope to Previously Excluded Gynecologic Cancer Patients

Roswell Park Comprehensive Cancer Center offers gynecologic cancer patients multidisciplinary care from nationally recognized specialists who collaborate on personalized treatment plans. According to Emese Zsiros, Md, PhD, FACOG, Chair of Gynecologic Oncology, what truly distinguishes their approach is access to innovative clinical trials unavailable elsewhere in the region.

Among their groundbreaking studies:

• A Complement Inhibitor Trial combining pathway inhibitors with checkpoint blockade for recurrent ovarian cancer patients with malignant effusions – a population often excluded from other trials. Early results show promising responses in both tumor control and fluid reduction.
• The CD40 Agonist Immunotherapy Trial which activates both B and T cells to enhance immune response against gynecologic cancers. This Roswell Park-led study is expanding to other leading institutions.
• As a national leader in Cell Therapy, Roswell Park offers trials utilizing CAR T-cells and tumor-infiltrating lymphocytes (TILs) for ovarian and uterine cancers- representing cutting-edge immunotherapy options.
• Their Digital Twin Technology Trial uses wearable devices to track real-time patient data, integrated with clinical information to build personalized treatment models.

Beyond innovate treatments, they offer integrated support services addressing the whole patient. Their strength in translational research also means laboratory discoveries reach clinical practice more rapidly, ensuring referring physicians can offer their patients treatment options at the forefront of gynecologic cancer care.